To understand the tumor-cell intrinsic effects of EZH2 inhibition, we treated four different NSCLC cell lines with the EZH2 inhibitors GSK126 or EPZ6438 for 5 days, followed by 2 days of EZH2 inhibition with IFNγ. The gene discussed is EZH2; the disease is non-small cell lung carcinoma.